Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00919191 · ClinicalTrials.gov registry record · Phase 4

Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Face

A Phase 4 study of Acne Vulgaris, sponsored by Bausch Health Americas.

Completed
Registry status
Phase 4
Development phase
26
Enrollment target
1
Study location

NCT00919191 is a Phase 4 study of Acne Vulgaris that has completed, run by Bausch Health Americas. The registered enrollment target is 26 participants, below the 275-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00919191, a Phase 4 study of Acne Vulgaris, has completed, sponsored by Bausch Health Americas.

COMPLETED
Registry status
Phase 4
Development phase
26 participants
Enrollment target
1
Study location

Study Summary

A study to compare the skin irritation potential of two marketed gels for acne treatment, each applied to half of the face of healthy volunteers.

Conditions Studied

Interventions

  • DRUG Tretinoin gel
  • DRUG Adapalene and Benzoyl peroxide

Study Locations (1)

Pennsylvania

  • Skin Study Center - Broomall

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2009-04
Est. Completion 2009-05
Phase Phase 4

Sponsor

Bausch Health Americas

168 total trials

What the Registry Record Tells You About NCT00919191

The ClinicalTrials.gov registry entry for NCT00919191 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 275-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (91% lower). The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 2 interventions - of which Tretinoin gel is the first listed.

NCT00919191 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00919191 about?

NCT00919191 is a clinical study titled "Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Face". A study to compare the skin irritation potential of two marketed gels for acne treatment, each applied to half of the face of healthy volunteers.

What is the current status of trial NCT00919191?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2009-04. Estimated completion is 2009-05.

What conditions does trial NCT00919191 study?

This clinical trial studies the following conditions: Acne Vulgaris.

What interventions are being tested in trial NCT00919191?

The interventions under investigation include: Tretinoin gel (DRUG), Adapalene and Benzoyl peroxide (DRUG).

Who is sponsoring clinical trial NCT00919191?

This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00919191 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acne Vulgaris

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.